株式会社GEXVal
2025年1月16日

GEXVal Completes Additional Funding of JPY 300 Million in Series C Extension Round and Forms Business Alliance with Alfresa Holdings Corporation

―Delivering Innovative Medicines to Patients Faster Through Circular Economy in Drug Discovery―

GEXVal Inc. (President & CEO Juran Kato, PhD; Location: Fujisawa, Kanagawa, Japan, “GEXVal”), is pleased to announce that it has entered into a basic agreement for capital and business alliance with Alfresa Holdings Corporation⁽¹⁾ (President & Representative Director: Ryuji Arakawa; Location: Chiyoda-ku, Tokyo, Japan, "Alfresa HD") and secured JPY 300 million through a third-party allotment of new shares ("Capital Increase") as part of Series C Extension Round. With this financing, the company has raised a cumulative total of JPY 860 million in its Series C Round, aimed at accelerating clinical development and enhancing the value of GXV-001⁽²⁾ while expanding business operations.

Under the basic agreement, GEXVal has granted Alfresa HD the right of first negotiation for primary drug distribution rights (account management rights) in Japan, upon marketing authorization approval of GXV-001⁽²⁾ as a pharmaceutical product in Japan. Both companies will continue discussions toward establishing a business alliance in Japan.

Mr. Ryuji Arakawa, Representative Director & President of Alfresa HD, commented, "Our group has identified 'improving patient access to pharmaceuticals' as one of the social values we aim to create through our business. Through collaboration with GEXVal in the development, manufacturing, distribution, and sales of GXV-001⁽²⁾, we will contribute to improving pharmaceutical access by delivering innovative medicines to patients as quickly as possible."

Dr. Juran Kato, President & CEO of GEXVal, commented: "We are entering a crucial stage with the Phase II clinical trial of GXV-001⁽²⁾. Through this collaboration with Alfresa HD, which brings extensive expertise across the pharmaceutical value chain, we are committed to delivering novel therapeutic options to patients and their families as quickly as possible. We will continue to strive for excellence in every aspect of our operations to bring medicines to those in need."

GEXVal strives to ensure Treatment Reaches the Unreached, focusing on rare diseases and underserved medical conditions. By leveraging its proprietary AI-driven pharmacoinformatics technology (RePhaIND^®(3)), the company illuminates paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver innovative, life-changing medicines that bring new hope to patients and their families.

(1) About Alfresa Holdings Corporation:
Representative: Ryuji Arakawa, Representative Director & President
Location: 1-1-3 Otemachi, Chiyoda-ku, Tokyo
Business Description: Management of subsidiaries engaged in wholesale distribution, manufacturing and marketing, import/export of pharmaceuticals, in-vitro diagnostics, medical devices and equipment, operation of dispensing pharmacies, and related businesses
URL: https://www.alfresa.com/

(2) About GXV-001:
GXV-001 has completed Phase I clinical trials through our wholly-owned subsidiary, GEXVal AU Pty Ltd. Currently, preparations are underway for Phase II clinical trials as a clinical development program for neurological disorders.

(3) About RePhaIND^®:
RePhaIND^® is our proprietary AI-driven technology platform. It efficiently identifies hidden relationships between drugs/drug candidates, their target mechanisms, and diseases to EMPOWER researchers with insights, ACCELERATE the drug discovery process, and REVOLUTIONIZE drug discovery.
Powered by RePhaIND^® - EMPOWER・ACCELERATE・REVOLUTIONIZE Drug Discovery

 

有关本事宜请咨询:
Head of Corporate office
Atsushi Sugizaki
info@gexval.com

 

End of document.